UBS maintains Clover Health Investments at Neutral, raises price target to $5.50 from $5

UBS kept its Neutral rating on Clover Health Investments but raised its price target to $5.50 from $5, a 10% increase. This implies a 22.8% upside from the Nov 5 close of $4.48, according to the firm.

Original reporting
Published Nov 6, 2026, 12:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Clover Health Investments at Neutral, raises price target to $5.50 from $5 — source image
Decision brief

The 30-second read

$CLOVBullishLow
01

Why it matters

The upgrade may prompt short‑term buying, but overall market reaction is expected to be modest.

02

Market read

A modest analyst upgrade with a new price target, offering limited trading opportunity.

03

What to watch

Potential regulatory risks and competition in the Medicare Advantage space.

Relevance 4/10Novelty 4/10Timing: today

Background

UBS issued a neutral rating with a higher price target for Clover Health Investments.

Company-level read

Ticker impact

$CLOVBullishMedium confidence
Context

UBS raised its price target on Clover Health Investments to $5.50 from $5, indicating potential upside.

Expected impact

likely modest upside as investors price in the higher target

Evidence & confidence

The new target suggests a 22.8% upside from the recent close, which could attract interest.

Market effects

May slightly lift other health‑tech stocks as analysts reassess valuations.

Limited to U.S. market participants focused on health‑tech.

Minimal global impact.

Counterpoint

The target raise could be premature if the company's growth outlook remains uncertain.

Key entities

  • Clover Health Investments

    U.S. health‑tech firm providing Medicare Advantage plans.

  • UBS

    Investment bank providing the rating and target.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.